Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Wuwei Huazhi Capsule
- Development stage
- Phase 3
- Lead developer
- Shijiazhuang Cangnuo Biotechnology
- Administration
- Oral
01
Overview
Wuwei Huazhi Capsule is a Traditional Chinese Medicine (TCM) herbal formulation developed by Shijiazhuang Cangnuo Biotechnology for the treatment of hemorrhoids. It is specifically indicated for patients presenting with the "damp-heat stagnation syndrome" (湿热瘀滞证) in TCM theory, which is often associated with symptoms such as hematochezia (rectal bleeding), pain, and swelling. The drug is administered orally in capsule form. Clinical development has reached Phase 3 in China, with studies focusing on its efficacy in reducing the time to disappearance of bleeding in patients with internal and mixed hemorrhoids.
- Brand names
- Wuwei Huazhi Capsule
- Other names
- 五味化痔胶囊
Beyond the preview
Go deeper on Wuwei Huazhi Capsule.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Wuwei Huazhi Capsule.